TIMELINE-Biogen’s Alzheimer’s drug hits brakes on Medicare coverage

April 8 (Reuters) – The U.S. government health plan for people over 65 on Thursday issued its final coverage policy for Biogen’s Alzheimer’s drug Aduhelm, moving forward with an unusually strict plan that would limited to patients in clinical trials. Below are the events of the drug’s controversial and prolonged approval last June and developments … Read more